Skip to content
Subscriber Only

Glaxo Memo Shows Drug Industry Lobbying on E-Cigarettes

GlaxoSmithKline Plc is pushing for more stringent regulation of electronic cigarettes, which compete with its Nicorette gum and other smoking cessation products, according to e-mails from a company executive.

Europe should follow the lead of the U.K., which plans to require e-cigarettes to be licensed as medicines much the way other nicotine-replacement therapy products are, wrote Sophie Crousse, the Brussels-based vice president of European public affairs for Glaxo’s consumer health-care division.